New findings presented on 10/16/18 by CytoReason reveals possible new cellular players in the tumor microenvironment that could impact the treatment process for the most in-need patients –... read more
New findings presented on 10/16/18 by CytoReason reveals possible new cellular players in the tumor microenvironment that could impact the treatment process for the most in-need patients –... read more
AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB) announced on 10/12/18 the pricing of an underwritten public offering of 16,537,500 shares of its common stock (or pre-funded warrants to... read more
Bristol-Myers Squibb Company (NYSE:BMY) announced on 8/12/18 topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,